Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers

摘要

Glucocorticoids are drugs that are controversial in the treatment of malignant tumors,especially in regimens using immune checkpoint inhibitors.Some oncologists warn that glucocorticoids might affect or even weaken the therapeutic efficacy of PD-1 inhibitors.Recently,Xiang et al.^(1) identified drugs that could target the dual-target of PD-L1/IDO1,and published their finding of“Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways”in Oncogene,a leading international oncology journal.